# US 2021/0330607 A1 · Binge behavior regulators

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0330607 A1
- Document ID: US20210330607A1
- Status: Published application
- Kind: A1
- Application number: 17/371,511
- Filed: 2021-07-09
- Published: 2021-10-28
- Earliest claimed: 2014-12-09
- Assignees: Clearmind Medicine Inc.
- Inventors: Ezekiel GOLAN
- Web page: https://patentgrep.com/patent/US20210330607A1

## CPC

- A61K 31/135: having aromatic rings {, e.g. ketamine, nortriptyline (methadone A61K31/137)}
- A23L 2/52: Adding ingredients (adding preservatives A23B70/10)
- A61K 31/255: of sulfoxy acids or sulfur analogues thereof
- A61K 31/357: having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K 31/36: Compounds containing methylenedioxyphenyl groups, e.g. sesamin
- A61K 31/40: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61P 25/30: for treating abuse or dependence
- A61P 25/32: Alcohol-abuse
- C12C 5/02: Additives for beer
- C12G 2200/21: Wine additives, e.g. flavouring or colouring agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12C: BEER; PREPARATION OF BEER BY FERMENTATION (ageing or ripening by storing C12H1/22; methods for reducing the alcohol content after fermentation C12H3/00; methods for increasing the alcohol content after fermentation C12H6/00; venting devices for casks, barrels or the like C12L9/00); PREPARATION OF MALT FOR MAKING BEER; PREPARATION OF HOPS FOR MAKING BEER
- C12G: WINE; PREPARATION THEREOF; ALCOHOLIC BEVERAGES (beer C12C); PREPARATION OF ALCOHOLIC BEVERAGES NOT PROVIDED FOR IN SUBCLASSES C12C OR C12H

## Abstract

Methods and compositions utilizing 2-aminoindan derivatives collectively represented by Formula I as described and defined in the specification for regulating binge behavior, particularly binge drinking, are disclosed.

## Claims

### Claim at position 1

1-22. (canceled)

### Claim 23

A method of regulating consumption of an alcoholic beverage, the method comprising administering to a subject in need thereof a pharmaceutically acceptable salt of 5-methoxy-2-aminoindan, thereby regulating consumption of the alcoholic beverage.

### Claim 24 (depends on 23)

The method of claim 23, wherein the consumption of the alcoholic beverage is associated with binge drinking.

### Claim 25 (depends on 23)

The method of claim 23, wherein the amount of alcohol consumption during a drinking session is reduced.

### Claim 26 (depends on 23)

The method of claim 23, wherein the pharmaceutically acceptable salt is administered before, simultaneously with, or subsequent to, consumption of the alcoholic beverage.

### Claim 27 (depends on 23)

The method of claim 23, wherein the pharmaceutically acceptable salt is administered simultaneously with the alcoholic beverage.

### Claim 28 (depends on 27)

The method of claim 27, wherein the pharmaceutically acceptable salt is incorporated in the alcoholic beverage.

### Claim 29 (depends on 28)

The method according to claim 28, wherein the amount of the pharmaceutically acceptable salt is in the range selected from 0.15 mg/ml to 0.60 mg/ml, 0.15 mg/ml to 0.5 mg/ml, 0.15 mg/ml to 0.40 mg/ml, 0.18 to 0.50 mg/ml, 0.18 to 0.40 mg/ml, 0.20 to 0.40 mg/ml, 0.20 to 0.30 mg/ml, 0.20 to 0.25 mg/ml, or 0.20 to 0.23 mg/ml.

### Claim 30 (depends on 23)

The method of claim 23, wherein the pharmaceutically acceptable salt forms a part of a composition, which further comprises a pharmaceutically acceptable carrier.

### Claim 31 (depends on 30)

The method of claim 30, wherein the composition is in a form of a free-flowing powder, a tablet, a capsule, a lozenge, a liquid, a liquid concentrate or a syrup.

### Claim 32 (depends on 30)

The method of claim 30, wherein the composition is a unit dosage form composition.

### Claim 33 (depends on 32)

The method of claim 32, wherein the pharmaceutically acceptable salt in the unit dosage form is in an amount ranging from 30 mg to 130 mg.

### Claim 34 (depends on 33)

The method of claim 33, wherein the amount of the pharmaceutically acceptable salt in the composition is 70 mg.

### Claim 35 (depends on 23)

The method of claim 23, wherein the pharmaceutically acceptable salt is administered to the subject orally.

### Claim 36 (depends on 35)

The method of claim 35, wherein the pharmaceutically acceptable salt is an acid addition salt.

### Claim 37 (depends on 36)

The method of claim 36, wherein the acid addition salt is a hydrochloric acid addition salt, a hydrobromic acid addition salt, ascorbic acid addition salt, a besylate addition salt, a camphorsulfonic acid addition salt, a citric acid addition salt, a malic addition salt, a methanesulfonic acid addition salt, a naphthalenesulfonic acid addition salt, an oxalic acid addition salt, a phosphoric acid addition salt, a p-toluenesulfonic acid addition salt, a p-succinic acid addition salt, a p-sulfuric acid addition salt, a p-tartaric acid addition salt, or a p-trifluoroacetic acid addition salt.

### Claim 38

A method of regulating binge behavior, the method comprising administrating to a subject in need thereof the pharmaceutically acceptable salt of 5-methoxy-2-aminoindan.

### Claim 39 (depends on 38)

The method of claim 38, wherein the pharmaceutically acceptable salt is an acid addition salt.

### Claim 40 (depends on 39)

The method of claim 39, wherein the acid addition salt is a hydrochloric acid addition salt, a hydrobromic acid addition salt, ascorbic acid addition salt, a besylate addition salt, a camphorsulfonic acid addition salt, a citric acid addition salt, a malic addition salt, a methanesulfonic acid addition salt, a naphthalenesulfonic acid addition salt, an oxalic acid addition salt, a phosphoric acid addition salt, a p-toluenesulfonic acid addition salt, a p-succinic acid addition salt, a p-sulfuric acid addition salt, a p-tartaric acid addition salt, or a p-trifluoroacetic acid addition salt.